Protocol Ledger

NCT05722938 · Phase III · RECRUITING

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

Interventional Phase III clinical trial protocol NCT05722938 sponsored by Biotest in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-09-09 Enrollment: 590 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05722938
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)590 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05722938
Protocol FieldVerified Registry Value
NCT IdentifierNCT05722938
Consolidated Lead SponsorBiotest
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment590 participants (ESTIMATED)
Registered Start Date2023-09-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI